Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis - PubMed (original) (raw)
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
T Moreau et al. Lancet. 1994.
Erratum in
- Lancet 1994 Aug 13;344(8920):486
Abstract
The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement. To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52). With some variations in the protocol, enhanced cerebral MR images were obtained monthly for 3-4 months before and at least 6 months after treatment. 28 enhancing areas were detected on the first series of 7 scans; 51 additional active lesions were identified on 18 scans before treatment; 15 were detected on 20 scans done over the next 3 months, but only 2 active lesions were seen on 23 scans during follow-up beyond 3 months. The difference in lesion incidence rate before and after treatment varied and the rate ratio was significantly reduced in only three patients. Collectively, in a "meta-analysis", the rate ratios were 0.15 [corrected] (95% CI 0.09-0.24) for all seven patients and 0.24 (0.14-0.42; p < 0.001) with exclusion of the patient whose scanning schedule differed. The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion. It is too early to say anything about the clinical results of treatment with this agent.
Similar articles
- Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.
Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C, Fieschi C. Bastianello S, et al. Neurology. 1990 Apr;40(4):591-5. doi: 10.1212/wnl.40.4.591. Neurology. 1990. PMID: 2320230 - Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, Hommes OR. Barkhof F, et al. AJR Am J Roentgenol. 1992 Nov;159(5):1041-7. doi: 10.2214/ajr.159.5.1414773. AJR Am J Roentgenol. 1992. PMID: 1414773 - Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.
Barkhof F, Tas MW, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, Valk J. Barkhof F, et al. Neuroradiology. 1994 Jul;36(5):382-7. doi: 10.1007/BF00612124. Neuroradiology. 1994. PMID: 7936181 - Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. Scott LJ, et al. CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review. - Magnetic resonance imaging in multiple sclerosis: an overview.
Colosimo M, Amatruda A, Cioffi RP. Colosimo M, et al. Ital J Neurol Sci. 1992 Dec;13(9 Suppl 14):113-23. Ital J Neurol Sci. 1992. PMID: 1345732 Review.
Cited by
- CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis.
Bogie JF, Grajchen E, Wouters E, Broux B, Stinissen P, Van Wijmeersch B, Hendriks JJ. Bogie JF, et al. Ther Adv Chronic Dis. 2020 Aug 21;11:2040622320947378. doi: 10.1177/2040622320947378. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 32913622 Free PMC article. - Alemtuzumab as Treatment for Multiple Sclerosis.
Katsavos S, Coles A. Katsavos S, et al. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029. doi: 10.1101/cshperspect.a032029. Cold Spring Harb Perspect Med. 2018. PMID: 29500306 Free PMC article. Review. - Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.
Guarnera C, Bramanti P, Mazzon E. Guarnera C, et al. Ther Clin Risk Manag. 2017 Jul 14;13:871-879. doi: 10.2147/TCRM.S134398. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28761351 Free PMC article. Review. - Alemtuzumab for Multiple Sclerosis.
Willis MD, Robertson NP. Willis MD, et al. Curr Neurol Neurosci Rep. 2016 Sep;16(9):84. doi: 10.1007/s11910-016-0685-y. Curr Neurol Neurosci Rep. 2016. PMID: 27485945 Free PMC article. Review. - ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Ruck T, Afzali AM, Lukat KF, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Wiendl H, Meuth SG. Ruck T, et al. BMC Neurol. 2016 Mar 10;16:34. doi: 10.1186/s12883-016-0556-9. BMC Neurol. 2016. PMID: 26966029 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical